Objective: We investigated the effects of mineral water fortified with folic acid, vitamins B 6 , B 12 , D and calcium on folate concentrations in serum and erythrocytes, serum vitamin B 12 and plasma homocysteine concentrations in free-living subjects. In addition, we investigated the bioavailability of calcium added to mineral water by measuring urinary calcium excretion and serum alkaline phosphatase activity. Design: Randomized, controlled, double-blinded, parallel design. Setting: Outpatient dietary intervention with free-living subjects in Eastern Finland. Subjects: Altogether, 66 subjects were recruited for the study. In all, 60 subjects completed the study. Interventions: The study began with a 2-week run-in period followed by an 8-week intervention period. During the intervention study, subjects consumed mineral water fortified with folic acid (563 mg/day), vitamins B 6 (1 mg/day), B 12 (7.5 mg/day), cholecalciferol (0.6 mg/day) and calcium (563 mg/day) or placebo mineral water. Results: The fortified mineral water increased serum and erythrocyte folate concentrations by 16.175.6 nmol/l (Po0.001) and 199776 nmol/l (Po0.001), respectively, and decreased plasma homocysteine concentration by 1.6 mmol/l (Po0.001). Urinary calcium excretion and serum alkaline phosphatase activity for 24 h increased significantly (Po0.001 and P ¼ 0.01 respectively) in the intervention group. Conclusions: Mineral water fortified with folic acid, vitamins B 6 , B 12 and D and calcium enhanced folate status and reduced plasma homocysteine concentration in normohomocysteinemic subjects without folate deficiency. Indirect measures of calcium and bone metabolism indicated that the calcium used in the fortification of the mineral water was bioavailable. Sponsorship: Olvi PLC, Iisalmi, Finland.
Introduction
It appears that low or inadequate folate status might contribute to the risk of developing congenital malformations, cardiovascular disease, certain malignancies and neurological dysfunction in the elderly (Molloy, 2002) . There is conclusive evidence that deficiency of folate in women of childbearing age increases the risk of neural-tube defects in the developing foetus. Consumption of supplements containing folic acid can reduce the incidence of neural-tube defects by as much as 75% (Chanarin, 1994; Law, 2000) . In 1992, the US Public Health Service recommended that all women of childbearing age should consume at least 400 mg/day of folic acid daily (Centers for Disease Control and Prevention, 1992) .
Nowadays all cereal and grain products are fortified with folic acid (at level 140 mg of folic acid per 100 g) to reduce the incidence of neural-tube defects in the US. Cereals fortified with folic acid have been shown to increase blood folate concentration in several intervention studies (Malinow et al, 1998; Schorah et al, 1998; Riddell et al, 2000; Venn et al, 2002) . There are also increasing data suggesting that in the US improved folate status can result from fortification of grain products (Rader, 2002) .
Folic acid supplementation alone or with vitamins B 6 and B 12 has reduced plasma homocysteine concentration effectively (Homocysteine Lowering Trialists ' Collaboration, 1998; Taylor et al, 2000) . In addition, there is evidence that cereals fortified with folic acid decrease total plasma homocysteine concentration (Malinow et al, 1998 (Malinow et al, , 2000 Schorah et al, 1998; Riddell et al, 2000; Venn et al, 2002) .
The results of epidemiological studies suggest that moderately elevated plasma or serum homocysteine concentrations are associated with an increased risk of cardiovascular disease (Eikelboom et al, 1999) . The association between homocysteine level and risk of cardiovascular disease is linear, and there is evidently no clear threshold level below which homocysteine is not associated with a risk of coronary heart disease (Arnesen et al, 1995; Nygård et al, 1997) . However, prospective studies offer weaker support than case-control studies for an association between homocysteine concentration and cardiovascular disease (Eikelboom et al, 1999; Ford et al, 2002) . Although Schnyder et al (2001 Schnyder et al ( , 2002 found that homocysteine lowering therapy using folic acid, vitamin B 12 and B 6 supplementation decreased the rate of restenosis and the rate of target lesion revascularization after coronary angioplasty, more evidence for the clinical benefit of reducing homocysteine levels is needed.
In Finland, the recommended daily intake of folate is 300 mg/day. Among Finnish women, the average daily intake of folate is below recommendation (240 mg), while intake in men barely meets the recommendation (300 mg) (National Public Health Institute, 1998) . In addition, in Finland, the intake of calcium and vitamin D is suboptimal especially among women (Kleemola et al, 1994; National Public Health Institute, 1998) . Low vitamin D and calcium intake are established risk factors for osteoporosis, and therefore optimizing the intake of these nutrients is important. A new type of mineral water fortified with folic acid, vitamins B 6 , B 12 and D and calcium was designed to supplement the diet with micronutrients with borderline intake, namely folic acid, calcium and vitamin D, to improve folate status and thus have a possible effect on homocysteine concentration.
In summary, the primary aim of the present study was to investigate the bioavailability of folic acid, vitamin B 12 and D and calcium from mineral water. The secondary aim of the study was to investigate the effect of the fortified mineral water on plasma homocysteine concentration.
Subjects and methods

Subjects
In all, 66 subjects were recruited to take part in the study. They fulfilled the following inclusion criteria: age 26-65 years, normal liver, kidney and thyroid function, and no history of unstable coronary artery disease (ie myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months), transient ischaemic attack, kidney stones or malignant diseases. Subjects with alcohol abuse (above 45 g of ethanol per day) or those that had used vitamin supplements (B or D vitamins) within 2 months prior to the study were excluded.
Of the 66 subjects screened, three were ineligible for randomization and one subject dropped out during the runin period for a personal reason. Of the 62 subjects who were randomized, 60 (39 men and 21 women) completed the study. Two subjects discontinued the study: one dropped out due to adverse effects (abdominal discomfort, diarrhoea, nausea and vomiting) of the test mineral water and one subject moved away. No one used any medication interfering with folate, vitamins B 6 , B 12 and D and calcium metabolism. Five of the subjects were regular smokers. Pretrial characteristics of the study subjects are presented in Table 1 . There were no significant differences in the baseline characteristics between the study groups. The study protocol was approved in the Ethics Committee of the Kuopio University Hospital The significance of difference between the groups analysed with independent samples t-test.
Fortified mineral water improves folate status NS Tapola et al and all subjects gave their informed consent at the pretrial visit.
Study design and diets
A randomized, placebo-controlled, double-blinded parallel study design was used (Figure 1 ). First, there was a 2-week run-in period before the baseline, during which the subjects were on their habitual diet. At baseline, the subjects were randomized into two groups: intervention group and control group. Men and women were randomized separately. In addition, the randomization was carried out separately for couples and single persons, in order to ensure the same mineral water for both spouses. During the intervention period, the subjects followed their habitual diet except that 750 ml of liquids were replaced with the mineral water. In total, 31 subjects drank test mineral water and 29 subjects drank control mineral water. The subjects were not allowed to use calcium supplements and foods fortified with calcium and/or any vitamin of B group during the study. The subjects visited the research unit four times after randomization: at 2, 4, 6 and 8 weeks.
Mineral water
The test mineral water was fortified with folic acid, vitamins B 6 (pyridoxine), B 12 (cyanocobalamin), D (cholecalciferol) and calcium (as calcium lactate). The mineral and vitamin composition of the test and control mineral water is presented in Table 2 . The fortified mineral water was produced in two batches. The other batch was made at the middle of the study. After 6 months, the folic acid, vitamin B 12 and vitamin D concentrations were reduced by 40, 85 and 75% in the test product, respectively. Stability data for 1 month are not available concerning the test product, but analysis from other batches indicate that folic acid, vitamin B 12 , and vitamin D concentrations reduce by 32, 70 and 50% during the first month, respectively. Calcium and vitamin B 6 concentrations of mineral water remain stable during both 1 month and 6 months of storage.
Health screening Previous and current diseases, current medication, alcohol consumption, smoking habits, physical activity and use of vitamins and other nutrient supplements were ascertained at the beginning of the study by interview using a structured questionnaire. The subjects were requested to keep their alcohol and tobacco consumption, physical activity and use of vitamins and other nutrient supplements constant during the study. A structured interview concerning alcohol and tobacco consumption was repeated at the end of the study.
Dietary monitoring
The subjects recorded daily their use of mineral water and the nutritionist checked the records at each visit. In addition, the subjects returned empty and partially empty bottles of mineral water to the study unit. The composition of the diet was monitored by a 4-day food record: once during the run-in period, and once during the intervention period, the subjects recorded dietary intake for four consecutive days in food records, including one weekend day or the person's day off from work. The serving sizes were estimated with a portion-size picture booklet (Haapa et al, 1985; Pietinen et al, 1988) . Oral and written instructions about how to record foods were given to all the subjects personally. At the study visits, the food records were checked by the nutritionist for completion, thus clarifying any missing information. The nutrients were calculated using Micro-Nutrica s (version 2.5) dietary analysis software (developed by The Social Insurance Institution, Turku, Finland), which is based on Finnish and international food composition data.
Measurements
Urinary samples for 24 h for calcium and creatinine analysis were collected once during the run-in period and once during the intervention period. Each participant received a container with hydrochloric acid (HCl) used as a preservative. To minimize loss of urine, the participants were given careful instructions in both oral and written form about the collection. The participant recorded the exact starting and ending time for collection. The volume of the urine sample was measured and a representative sample of 10 ml was obtained for analysis. A 24 h urinary creatinine excretion measurement was taken to ensure the completeness of urine collection. Urine samples of two subjects were not analysed because of incomplete collection. Body weight was measured twice at every visit using a digital scale (Scale Seca 707, Vogel & Falke GmpH & Co, Hamburg, Germany). The mean value of the two measurements was used in the analyses.
Venous blood samples were obtained after a 12-h overnight fast. Blood pressure measurements were performed after 10 min rest in the sitting position with a mercury sphygmomanometer (Mercuro 300, Speidel & Keller GmpH & Co, Jungingen, Germany) three times on every occasion. The mean value of the last two measurements was used in the analyses.
Biochemical assays
For the determination of plasma homocysteine, blood samples were centrifuged at 2000 rcf for 10 min immediately after venipuncture. Plasma was separated and stored at À221C in plastic tubes. All frozen samples were shipped with dry ice for analysis at the same time. . The total analytic interassay coefficient of variation was 8% (n ¼ 16) for the plasma homocysteine assay and systematic bias was 8% (n ¼ 16).
All other analyses were carried out at the Clinical Chemistry Unit, Kuopio University Hospital. Serum and erythrocyte folate were measured using the AutoDELFIA Folate time-resolved fluoroimmunoassay method (TR-FIA) (Perkin Elmer Wallac, Turku, Finland). Folate was measured in serum or whole-blood haemolysate with a competitive reaction between europium-labelled pteroylglutamic acid and sample folate for a limited amount of folate-binding protein. The assay involved a chemical pretreatment step to release folate from carrier proteins and convert it into a stable, measurable form. In the erythrocyte folate measurement, the whole EDTA-blood was haemolysed with 0.5% ascorbic acid for 20 h before analysis. After measurement, the folate concentration was divided by the haematocrit value to obtain the erythrocyte folate concentration. In the serum folate assay, intra-and interassay coefficients of variation were 1.2-3.8 and 4.1-8.6% in the concentration range of 3.5-34 nmol/l and in the erythrocyte folate assay 1.5-1.7 and 4.1-8.2%, respectively. Serum vitamin B 12 was measured by a competitive AutoDELFIA B 12 TR-FIA method using intrinsic factor as the binding protein in the assay. In the pretreatment step of the assay, vitamin B 12 was chemically released from the carrier proteins. The intra-and interassay coefficients of variation were 1.7-4.1 and 4.8-8.4%.
Urinary creatinine was analysed by kinetic Jaffe reaction on a Konelab 60i analyser (Labsystems CLD, Konelab, Finland) with a commercial kit (Konelab, CREATININE, 981374). The intra-and interassay coefficients of variation were 2.2-2.4 and 3.6-12.2%, respectively. Serum calcium was analysed by spectrophotometric test using Arsenazo III on a Konelab 60i analyzer with a commercial kit (Konelab CALCIUM, 981367). In the serum calcium assay, the intraand interassay coefficients of variation were 0.4-0.8 and 1.1-4.1%, respectively. Urinary calcium was analysed by atomic absorption spectrophotometry. Serum alkaline phosphatase activity was determined on a Konelab 60i analyser with a commercial kit (Konelab AFOS (DEA), 981359) (The Committee on Enzymes of the Scandinavian Society, 1974). The intra-and interassay coefficients of variation were 1.0-2.7 and 5.0-8.8%, respectively.
Laboratory samples for routine haematology (blood count, serum thyroid-stimulating hormone, glutamyltransferase, creatinine, urate) were collected and analysed at the Clinical Chemistry Unit, Kuopio University Hospital. Plasma glucose was analysed at the Clinical Research Unit, University of Kuopio, using commercial reagents (Granutest 100 Glucose, Merck, Germany) by enzymatic photometric method with a Kone Pro Analysator (Kone Corporation, Espoo, Finland).
Statistical analyses
The data were analysed with the SPSS Base and Advanced models 10.1 statistics program (SPSS Inc, Chicago, USA). The results are given as group means and standard deviations. Normal distribution of variables was checked with the Shapiro-Wilk test before further analyses. The equality of variances between the groups was tested with the Levene test for homogeneity of variance. The differences in the pretrial characteristics and in the absolute and percentage changes in variables between the groups were tested with an independent samples t-test. Intake of cholesterol and vitamin D, serum folate and vitamin B 12 concentrations were logarithmically transformed for analyses. The general linear model (GLM) repeated-measures procedure was used to test between-group and within-group differences in the repeated continuous variables. When the group effect was significant (Po0.05), an independent samples t-test with a Bonferroni correction was used in further analyses. When the analysis indicated that the overall change in a variable with time was significant (Po0.05), or when the time*group interaction was significant (Po0.05), the change over time within each group was assessed using a GLM repeated-measures proce-dure. For the variables that were not normally distributed even after logarithmic or other mathematical transformation, and also in cases where the groups' variances were unequal, the Mann-Whitney test (between-groups) and the Friedman and Wilcoxon test (within group) were used. The sign test was used to compare the variables of smoking habits, alcohol consumption and physical activity. For some variables of interest, Spearman correlation coefficients were calculated.
The number of subjects recruited for the study was based on the assumption of a 2.0 mmol/l difference in homocysteine concentration and 117 nmol/l difference in erythrocyte folate concentration between the groups significant with an a-level of 0.05 and with 0.80 statistical power.
Results
Dietary compliance
Body weight decreased 0.271.8 kg in the intervention group and 0.771.1 kg in the control group (Po0.05 between the groups). Physical activity, alcohol consumption and smoking habits remained stable.
There were no significant differences in nutrient intakes between the groups at the baseline (Table 3) . During the intervention period, the only differences in diet between the groups were due to calcium, folic acid and vitamin B 12 fortification of test mineral water. The intake of calcium, folic acid, vitamins B 6 and B 12 was higher during the intervention period compared to the baseline in the intervention group. The energy and nutrient intake remained stable in the control group during the study. The intervention group drank 99% of mineral water portions and the control group drank 98% of mineral water portions during the study. Dietary compliance was verified by checking the records completed and mineral water bottles returned by the study subjects. According to the food records, the mean daily intake of mineral water was 75070 ml in the intervention group and 743735 ml in the control group. Altogether, the compliance in the use of the mineral water was good.
Serum and erythrocyte folate and serum vitamin B 12 concentrations The mean serum and erythrocyte folate and serum vitamin B 12 concentrations at the baseline were not significantly different between the groups (Table 4) . Serum folate concentrations at weeks 2, 4 and 8 and erythrocyte folate concentrations at week 8 were higher in the intervention group in comparison with the control group. During the 8 weeks of intervention, serum folate concentrations increased 16.175.6 nmol/l in the intervention group, but remained unchanged in the control group (Po0.001 between the groups). Erythrocyte folate concentrations increased 199776 nmol/l in the intervention group and decreased 27757 nmol/l in the control group (Po0.001 between the groups). There were no significant differences in serum vitamin B 12 concentrations between the groups at the end of the intervention. However, an increase of 32760 pmol/l in serum vitamin B 12 concentrations was found in the intervention group, with no change in the control group (P ¼ 0.020 between the groups).
The differences in percentage changes in serum and erythrocyte folate and serum vitamin B 12 concentrations between the groups were thus statistically significant (Figure 2 ).
Plasma homocysteine concentrations
There were no differences in plasma homocysteine concentrations at the baseline between the groups (Table 4) . At the end of the study, plasma homocysteine concentrations were higher in the control group compared to the intervention group. Plasma homocysteine concentrations decreased 1.671.2 mmol/l (18712%) in the intervention group and increased 0.371.7 mmol/l (4721%) in the control group (Po0.001 between the groups). The decrease in the concentration of plasma homocysteine in the intervention group was the same for both men and women (1.671.2 and 1.671.1 mmol/l, respectively).
The change in the intake of folate and vitamin B 6 from baseline to intervention period showed a significant inverse correlation with the change in plasma homocysteine concentration from baseline to 8 weeks in the entire group (r ¼ À0.44, Po0.001, r ¼ À0.33, P ¼ 0.010, respectively). The change in the intake of any other fortified nutrient did not correlate significantly with the change in plasma homocysteine concentration. In addition, the change in the serum and erythrocyte folate concentration showed a significant inverse correlation with the change in plasma homocysteine concentration (r ¼ À0.57, Po0.001 for both), and the correlation between the change in the serum vitamin B 12 concentration and the change in plasma homocysteine concentration was not significant (r ¼ À0.14, P40.5).
Urinary calcium excretion, serum calcium and alkaline phosphatase There were no significant differences in 24-h urinary calcium excretion between the groups at baseline or at week 6 (Table 4) . However, 24-h urinary calcium excretion increased by 1.1 mmol in the intervention group and remained stable in the control group (P ¼ 0.001 between the groups). The difference in the percentage change in urinary calcium excretion was statistically significant (Figure 2 ).
There were no significant differences in serum calcium concentrations and serum alkaline phosphatase activity levels between the groups at baseline or at week 6 (Table 4) . Serum alkaline phosphatase activity decreased from the baseline in the intervention group, but remained stable in the control group.
Blood pressure There were no significant differences in systolic or diastolic blood pressure between the groups. Systolic blood pressure was 132716 and 127718 mmHg at the beginning of the intervention period and 129716 and 124715 mmHg at the end of the intervention period in the intervention and control group, respectively. Diastolic blood pressure was 8479 and 81711 mmHg at the beginning of the intervention period and 8279 and 81710 mmHg at the end of the intervention period in the intervention and control group, respectively. Systolic blood pressure decreased statistically significantly in the control group, whereas the diastolic blood pressure decreased statistically significantly in the intervention group. In further statistical analyses, the difference in diastolic blood pressure between the baseline and the end of the intervention period was not statistically significant in the intervention group, and there were no statistically significant differences in the change of systolic or diastolic blood pressure between the groups.
Discussion
The aim of the present study was to investigate the effect of the mineral water fortified with folic acid (563 mg/day), vitamins B 6 (1 mg/day) , B 12 (7.5 mg/day), D (0.6 mg/day) and calcium (563 mg/day) on serum and erythrocyte folate concentrations, serum vitamin B 12 concentrations, plasma homocysteine concentrations and urinary calcium excretion in men and women. A randomized, placebo-controlled parallel design with an 8-week test period was used. The parallel design was used because of the slow turnover of the whole-body folate pool. It has been shown that blood folate Reference interval in healthy subjects for serum folate 6.2-40 nmol/l (Perkin-Elmer Wallac, Turku, Finland), for erythrocyte folate 315-850 nmol/l (Perkin-Elmer Wallac, Turku, Finland), for serum vitamin B 12 140-540 pmol/l (Perkin-Elmer Wallac, Turku, Finland), for plasma homocysteine 5-15 mmol/l (Ahola, 2001) , for serum calcium 2.2-2.65 mmol/l (Kuopio University Hospital, Kuopio, Finland), for serum alkaline phosphatase 50-250 U/l (Penttilä et al, 1975) and for urinary calcium excretion 1.25-7.5 mmol/24 h (Hammarsten, 1955) . a
The significance of overall difference between the groups analysed with the GLM for repeated measures. b The significance of difference within the groups analysed with the GLM for repeated measures. and plasma homocysteine concentrations do not return to the baseline during the 8-week washout period after folic acid supplementation (Brouwer et al, 1999) . Vitamins B 6 and B 12 were used in combination because of the inter-relationship of these vitamins with folic acid.
The study subjects' physical activity, smoking habits, alcohol consumption and energy intake remained stable during the study. Nutrient intake was not significantly different between the groups and there were no significant changes in the background diet in either of the groups. All changes in nutrient intake in the intervention group and all the differences between the groups were due to the calcium and vitamin fortification of the test mineral water. Body weight was lowered by 0.7 kg in the control group, but remained stable in those subjects who received fortified mineral water. Therefore, changes in plasma homocysteine, serum and erythrocyte folate and serum B 12 concentrations and urinary calcium excretion can be ascribed to the use of the test mineral water.
Mineral water fortified with folic acid, vitamins B 6 , B 12 , D and calcium increased serum and erythrocyte folate concentrations and serum vitamin B 12 concentrations and decreased plasma homocysteine concentrations significantly during the 8-week intervention period. In several studies, folic acid has been shown to reduce plasma homocysteine concentrations. Table 5 shows some previous studies of folic acid supplementation in which the daily amount of folic acid (400-600 mg) is comparable to the present study. The maximum effect of folic acid on serum homocysteine concentration has been shown to occur at a daily dose of 800 mg (Wald et al, 2001) . Several studies have shown that reduction in homocysteine concentrations is dependent on baseline homocysteine concentration; subjects with high initial plasma homocysteine concentrations respond to folic acid treatment with larger reductions than subjects with low initial homocysteine concentrations (Brönstrup et al, 1998; den Heijer et al, 1998; Brouwer et al, 1999; Wald et al, 2001) . The study population of the present study was normohomocysteinemic with a mean baseline homocysteine value of 8.7 mmol/l. In the study of Brouwer et al (1999) , the mean plasma homocysteine concentration of subjects in the second quintile of initial plasma homocysteine concentration was 8.9 mmol/l. In those subjects, folic acid (500 mg/day) supplementation caused a decrement in the plasma homocysteine concentration parallel to our study. However, the mean decrease in plasma homocysteine was 2.6 mmol/l in the whole study population when subjects with high homocysteine concentrations were included in the analysis.
Fortified mineral water increased serum and erythrocyte folate concentrations by 150 and 45%, respectively. The Brönstrup et al (1998) and Brouwer et al (1999) (Table 5) . Fortified mineral water in the present study caused an increase in serum vitamin B 12 concentration. Due to the lower baseline concentration of serum vitamin B 12 in the intervention group, there was no significant difference in mean values of serum vitamin B 12 between the groups at the end of the study. Observed increment in serum vitamin B 12 concentration accords with the study of Brönstrup et al (1998) . Vitamin B 12 is a cofactor of methionine synthase, the enzyme catalysing the formation of methionine from homocysteine. In a previous meta-analysis, vitamin B 12 combined with folic acid supplementation was associated with an additional 7% reduction in plasma homocysteine concentration in comparison with folic acid alone when the mean dose of vitamin B 12 was 500 mg (Homocysteine Lowering Trialists, 1998). In the study of Brönstrup et al (1998) , plasma homocysteine concentration decreased more after folic acid supplementation in combination with vitamin B 12 (6 mg) in comparison with plain folic acid (400 mg), but the difference was not statistically significant. In our study, the change in the intake of either vitamin B 12 or serum vitamin B 12 concentration showed no significant correlation with the change in plasma homocysteine concentration. It is recommended to give vitamin B 12 in combination with folic acid supplementation, because folate administration alone might mask vitamin B 12 deficiency (Boushey et al, 1995) . In the initial treatment of pernicious anaemia (severe atrophic gastritis), an oral daily dose at least 1 mg of vitamin B 12 is needed. The vitamin B 12 content of the mineral water in this study is absorbable by healthy subjects, and corresponds to the prophylactic doses in prescription-free tablets designated for subjects with reduced intake but normal absorption of vitamin B 12 .
According to the meta-analysis of randomized controlled studies that assessed the effects of folic acid-based supplements on blood homocysteine concentrations, supplementation with vitamin B 6 does not have any significant additional effect on homocysteine concentrations (Homocysteine Lowering Trialists' Collaaboration, 1998) . In the present study, the change in the intake of vitamin B 6 showed a significant inverse correlation with the change in plasma homocysteine concentration. This result indicates that intake of vitamin B 6 might have affected plasma homocysteine concentration in the present study. Unfortunately, there are no data available for biochemical indices of vitamin B 6 during the study to confirm the role of B 6 fortification in the reduction of plasma homocysteine concentrations. However, the strongest inverse correlations were found between the change in plasma homocysteine concentration and the change in the intake of both folate and serum and erythrocyte folate concentrations.
Mineral water fortified with 563 mg of calcium and vitamins increased 24-h urinary calcium excretion by 1.1 mmol (27%) from the baseline. This result is similar to that found in previous studies with calcium supplements given as calcium carbonate. In the study of Kawano et al (1998) , 1 g of calcium carbonate increased urinary calcium excretion by 1.3 mmol (27%). In the study of Williams et al (2001) , 500 mg calcium carbonate increased calcium excretion 0.96 mmol (10.2 %), and in the study of Fardellone et al (1998) , 1200 mg of calcium increased calcium excretion by 1.4 mmol/l (39%). Increase in urinary calcium excretion has been considered as a surrogate marker of calcium absorption. However, these results should be interpreted with caution, because it is also possible that the increased intake of calcium and vitamin D could have suppressed serum parathyroid hormone levels (not measured here) and thus renal calcium reabsorption could have been diminished, resulting in a somewhat increased urinary loss of calcium. Serum calcium concentrations did not change during the study. This finding was expected, because serum calcium concentration is strictly controlled by calcitrophic hormones (vitamin D and parathyroid hormone). Serum total alkaline phosphatase activity decreased in the intervention group. In this context, the changes in total activity of this enzyme are most likely due to a decrease in bone isoenzyme activity, which is widely used as a marker of bone formation. As bone formation and resorption are tightly coupled and in balance, the change in any marker reflects the overall rate of bone turnover (Delmas & Garnero, 1998) and thus the overall effects of the mineral water on bone metabolism are to be considered favourable.
Systolic blood pressure decreased in the control group and diastolic blood pressure decreased in the intervention group. However, the difference in the diastolic blood pressure between the baseline and the end of the intervention period was not significant in the intervention group. Therefore, it is likely that the observed decreases in blood pressure levels were mainly due to chance, or regression to the mean, or to the subjects becoming accustomed to the blood pressure measurements.
In conclusion, mineral water fortified with folic acid (563 mg/day), vitamins B 6 (1 mg/day), B 12 (7.5 mg/day), D (0.6 mg/day) and calcium (563 mg/day) increased serum and erythrocyte folate and serum vitamin B 12 concentrations and decreased plasma homocysteine concentrations in normohomocysteinaemic subjects. In addition, this mineral water evidently had favourable effects on bone metabolism. Fortified mineral water will increase the number of products fortified with folic acid and therefore may help to ensure that populations achieve the desired increase of folate intake, especially in countries without a mandatory folic acid fortification policy.
